These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 6387123)
1. Survey of the human acetylator polymorphism in spontaneous disorders. Evans DA J Med Genet; 1984 Aug; 21(4):243-53. PubMed ID: 6387123 [TBL] [Abstract][Full Text] [Related]
2. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Clark DW Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977 [TBL] [Abstract][Full Text] [Related]
3. The association of the slow acetylator phenotype with bladder cancer. Evans DA; Eze LC; Whibley EJ J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762 [TBL] [Abstract][Full Text] [Related]
4. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism]. Furet Y; Bechtel Y; Le Guellec C; Bechtel PR; Autret-Leca E; Paintaud G Therapie; 2002; 57(5):427-31. PubMed ID: 12611196 [TBL] [Abstract][Full Text] [Related]
6. Lack of association between slow acetylator status and spontaneous lupus erythematosus. Kumana CR; Chan MM; Wong KL; Wong RW; Kou M; Lauder IJ Clin Pharmacol Ther; 1990 Aug; 48(2):208-13. PubMed ID: 2379389 [TBL] [Abstract][Full Text] [Related]
8. Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2'-dimethyl-4-aminobiphenyl. Feng Y; Fretland AJ; Rustan TD; Jiang W; Becker WK; Hein DW Toxicol Appl Pharmacol; 1997 Nov; 147(1):56-62. PubMed ID: 9356307 [TBL] [Abstract][Full Text] [Related]
9. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. Yu MC; Skipper PL; Taghizadeh K; Tannenbaum SR; Chan KK; Henderson BE; Ross RK J Natl Cancer Inst; 1994 May; 86(9):712-6. PubMed ID: 8158701 [TBL] [Abstract][Full Text] [Related]
10. Clinical consequences of polymorphic acetylation of basic drugs. Drayer DE; Reidenberg MM Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187 [TBL] [Abstract][Full Text] [Related]
11. Polymorphic acetylator phenotype and systemic lupus erythematosus. Johansson E; Mustakallio KK; Mattila MJ Acta Med Scand; 1981; 210(3):193-6. PubMed ID: 6974957 [TBL] [Abstract][Full Text] [Related]
12. Ethnic differences in reactions to drugs and xenobiotics. Acetylation. Evans DA Prog Clin Biol Res; 1986; 214():209-42. PubMed ID: 3523508 [No Abstract] [Full Text] [Related]
17. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Golka K; Prior V; Blaszkewicz M; Bolt HM Toxicol Lett; 2002 Mar; 128(1-3):229-41. PubMed ID: 11869833 [TBL] [Abstract][Full Text] [Related]
18. Hepatic acetylator phenotype in bladder cancer patients. Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447 [TBL] [Abstract][Full Text] [Related]
19. Antinuclear antibodies related to acetylator phenotype in mice. Tannen RH; Weber WW J Pharmacol Exp Ther; 1980 Jun; 213(3):485-90. PubMed ID: 6970809 [TBL] [Abstract][Full Text] [Related]
20. The lack of relationship between acetylator phenotype and idiopathic systemic lupus erythematosus in a South-east Asian population: a study of Indians, Malays and Malaysian Chinese. Ong ML; Mant TG; Veerapen K; Fitzgerald D; Wang F; Manivasagar M; Bosco JJ Br J Rheumatol; 1990 Dec; 29(6):462-4. PubMed ID: 2257457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]